Molecular biomarkers in urothelial carcinoma of the bladder

Are we there yet?

George J. Netto

Research output: Contribution to journalArticle

Abstract

The unprecedented advances in cancer genetics and genomics are rapidly affecting the clinical management of solid tumors. Molecular diagnostics are now an integral part of routine clinical management for patients with lung, colon, and breast cancer. In sharp contrast, molecular biomarkers have been largely excluded from current management algorithms for urologic malignancies. The need for new treatment options that can improve upon the modest outcomes currently associated with muscle-invasive bladder cancer is evident, and validated prognostic molecular biomarkers that can help clinicians to identify patients in need of early, aggressive management are lacking. Robust predictive biomarkers that are able to forecast and stratify responses to emerging targeted therapies are also needed.

Original languageEnglish (US)
Pages (from-to)41-51
Number of pages11
JournalNature Reviews Urology
Volume9
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Urinary Bladder
Biomarkers
Carcinoma
Neoplasms
Molecular Pathology
Genomics
Urinary Bladder Neoplasms
Colonic Neoplasms
Lung Neoplasms
Breast Neoplasms
Muscles
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

Molecular biomarkers in urothelial carcinoma of the bladder : Are we there yet? / Netto, George J.

In: Nature Reviews Urology, Vol. 9, No. 1, 01.2012, p. 41-51.

Research output: Contribution to journalArticle

@article{44f3d017a8134288b05150c3b8edd98a,
title = "Molecular biomarkers in urothelial carcinoma of the bladder: Are we there yet?",
abstract = "The unprecedented advances in cancer genetics and genomics are rapidly affecting the clinical management of solid tumors. Molecular diagnostics are now an integral part of routine clinical management for patients with lung, colon, and breast cancer. In sharp contrast, molecular biomarkers have been largely excluded from current management algorithms for urologic malignancies. The need for new treatment options that can improve upon the modest outcomes currently associated with muscle-invasive bladder cancer is evident, and validated prognostic molecular biomarkers that can help clinicians to identify patients in need of early, aggressive management are lacking. Robust predictive biomarkers that are able to forecast and stratify responses to emerging targeted therapies are also needed.",
author = "Netto, {George J.}",
year = "2012",
month = "1",
doi = "10.1038/nrurol.2011.193",
language = "English (US)",
volume = "9",
pages = "41--51",
journal = "Nature Reviews Urology",
issn = "1759-4812",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Molecular biomarkers in urothelial carcinoma of the bladder

T2 - Are we there yet?

AU - Netto, George J.

PY - 2012/1

Y1 - 2012/1

N2 - The unprecedented advances in cancer genetics and genomics are rapidly affecting the clinical management of solid tumors. Molecular diagnostics are now an integral part of routine clinical management for patients with lung, colon, and breast cancer. In sharp contrast, molecular biomarkers have been largely excluded from current management algorithms for urologic malignancies. The need for new treatment options that can improve upon the modest outcomes currently associated with muscle-invasive bladder cancer is evident, and validated prognostic molecular biomarkers that can help clinicians to identify patients in need of early, aggressive management are lacking. Robust predictive biomarkers that are able to forecast and stratify responses to emerging targeted therapies are also needed.

AB - The unprecedented advances in cancer genetics and genomics are rapidly affecting the clinical management of solid tumors. Molecular diagnostics are now an integral part of routine clinical management for patients with lung, colon, and breast cancer. In sharp contrast, molecular biomarkers have been largely excluded from current management algorithms for urologic malignancies. The need for new treatment options that can improve upon the modest outcomes currently associated with muscle-invasive bladder cancer is evident, and validated prognostic molecular biomarkers that can help clinicians to identify patients in need of early, aggressive management are lacking. Robust predictive biomarkers that are able to forecast and stratify responses to emerging targeted therapies are also needed.

UR - http://www.scopus.com/inward/record.url?scp=84855227050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855227050&partnerID=8YFLogxK

U2 - 10.1038/nrurol.2011.193

DO - 10.1038/nrurol.2011.193

M3 - Article

VL - 9

SP - 41

EP - 51

JO - Nature Reviews Urology

JF - Nature Reviews Urology

SN - 1759-4812

IS - 1

ER -